Age, Biography and Wiki

Kent Holtorf was born on 23 June, 1964 in United States, is a Kent Holtorf is physician. Discover Kent Holtorf's Biography, Age, Height, Physical Stats, Dating/Affairs, Family and career updates. Learn How rich is he in this year and how he spends money? Also learn how he earned most of networth at the age of 59 years old?

Popular As N/A
Occupation Medical Doctor
Age 59 years old
Zodiac Sign Cancer
Born 23 June, 1964
Birthday 23 June
Birthplace N/A
Nationality United States

We recommend you to check the complete list of Famous People born on 23 June. He is a member of famous Doctor with the age 59 years old group.

Kent Holtorf Height, Weight & Measurements

At 59 years old, Kent Holtorf height not available right now. We will update Kent Holtorf's Height, weight, Body Measurements, Eye Color, Hair Color, Shoe & Dress size soon as possible.

Physical Status
Height Not Available
Weight Not Available
Body Measurements Not Available
Eye Color Not Available
Hair Color Not Available

Dating & Relationship status

He is currently single. He is not dating anyone. We don't have much information about He's past relationship and any previous engaged. According to our Database, He has no children.

Family
Parents Not Available
Wife Not Available
Sibling Not Available
Children Not Available

Kent Holtorf Net Worth

His net worth has been growing significantly in 2023-2024. So, how much is Kent Holtorf worth at the age of 59 years old? Kent Holtorf’s income source is mostly from being a successful Doctor. He is from United States. We have estimated Kent Holtorf's net worth, money, salary, income, and assets.

Net Worth in 2024 $1 Million - $5 Million
Salary in 2024 Under Review
Net Worth in 2023 Pending
Salary in 2023 Under Review
House Not Available
Cars Not Available
Source of Income Doctor

Kent Holtorf Social Network

Instagram
Linkedin
Twitter Kent Holtorf Twitter
Facebook Kent Holtorf Facebook
Wikipedia Kent Holtorf Wikipedia
Imdb

Timeline

1964

Kent Holtorf (born 1964) is an American physician and entrepreneur practicing in Los Angeles, California.

He is a board examiner of the American Board of Anti-Aging Medicine (ABAAM), which is not recognized by established medical organizations.

He is the founder and medical director of Holtorf Medical Group, a practice with five centers that offer treatment for conditions including fibromyalgia, adrenal fatigue (a non-existent condition), complex endocrine dysfunction, hypothyroidism, age management, chronic fatigue syndrome, low libido, chronic Lyme disease, migraines, PMS, perimenopause and menopause.

His practice focuses on alternative therapies that are not recognised as effective.

He has been criticized in the media for his controversial views on topics like bioidentical hormone replacement therapy and vaccines.

Holtorf is a graduate of the University of California at Los Angeles.

He is also a graduate of the St. Louis University School of Medicine, where he received his doctorate of medicine then returned to UCLA for residency training.

1994

He has maintained a clinical practice since 1994 and is a former medical director of the Fibromyalgia and Fatigue Centers, Inc. (FFC).

Holtorf has published a number of endocrine reviews on complex topics in peer-reviewed journals on controversial diseases and treatments.

He is a guest editor and peer-reviewer for a number of medical journals including Endocrine, is the current AOL Health Expert in Endocrinology, and is a diplomate and board examiner of the American Board of Anti-Aging Medicine (ABAAM).

He is a founding member of The Bioidentical Hormone Initiative (BHI), and a founder and director of the National Academy of Hypothyroidism (NAH).

2001

In 2001, Holtorf established the Holtorf Medical Group.

Holtorf has been the subject of criticism online and in the media for several years for his promotion of controversial diagnostic methods.

He has been an advocate of bioidentical hormones, which has been labeled as quackery.

He published an extensive review on the safety and efficacy of bioidentical hormones in the peer-reviewed journal Post Graduate Medicine.

The review concluded, “Physiological data and clinical outcomes demonstrate that bioidentical hormones are associated with lower risks, including the risk of breast cancer and cardiovascular disease, and are more efficacious than their synthetic and animal derived counterparts.

Until evidence is found to the contrary, bioidentical hormones remain the preferred method of HRT.

Further randomized controlled trials are needed to delineate these differences more clearly.” The conclusions were contrary to mainstream opinions on the use of bioidentical hormones.

Additionally, many argue that the extensive use of compounded bioidentical hormones is risky because they can be inconsistent and unstable and are not always subject to FDA oversight.

Holtorf has also taken an unpopular stance that children are over vaccinated and that vaccines may be associated with autism.

Televised appearances and interviews have put Holtorf's views front and center and invited criticism and debate.

2009

Among them, his 2009 appearance on Fox News in regards to the H1N1 vaccine, in which Holtorf plainly states he "definitely would not" administer the controversial vaccine to his own children, is one of the most highly deliberated.

Holtorf likewise links high levels of vaccine adjuncts, such as mercury, to some cases of autism development in children during the interview and is questionably identified on the program as an infectious disease expert.

This view is contrary to the position statements of agencies such as the Center for Disease Control and the Institute of Medicine, and societies such as the American Academy of Pediatrics, who state that there is no credible evidence that vaccines have any link to autism.

Holtorf states that the standard thyroid tests which are typically relied upon by primary care and specialist physicians to diagnosis hypothyroidism (low thyroid) and determine dosage are insufficient because they focus on TSH levels as an indicator of thyroid function and miss a large percentage of people with low thyroid.

This is discussed extensively on the website of his nonprofit organization the National Academy of Hypothyroidism.

Instead, Holtorf advocates labs and diagnostics which look at all thyroid hormone levels, with a particular emphasis on free T3, triodothyronine, the active hormone both produced by the thyroid and converted from T4, levothyroxine, and reverse T3, a metabolite of T4 conversion usually created during times of stress or trauma.

This is contrary to position statements by societies such as the American Thyroid Association and American Association of Clinical Endocrinologist.

Holtorf condones treating hypothyroidism with compounded combinations of bioidentical thyroid hormones.

Chronic fatigue syndrome (CFS) and fibromyalgia are two separate disorders that share many overlapping symptoms and are often cross-diagnosed.

FDA approved therapies for the treatment of fibromyalgia include Cymbalta (duloxetine hydrochloride), Lyrica (pregabalin), and Savella (milnacipran HCL); while there are no FDA approved medications for the treatment of chronic fatigue syndrome.

Other medications that are commonly used include tryicylcic antidepressants, SSRI antidepressants, Nonsteroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants.

In contrast, Dr Holtorf advocates a controversial six step plan that involves the treatment of hormone imbalances, mitochondrial dysfunction, sleep disturbances, and chronic infections.

The Infectious Disease Society of America states that Lyme disease is easily treated with a few weeks of antibiotics and that chronic Lyme disease does not exist.

Their position is that standard blood tests are an accurate means of determining the presence of Lyme disease.

Holtorf maintains a controversial stance that weight loss is not an issue of diet and exercise, citing causes for the inability to lose weight as leptin resistance, undiagnosed hypothyroidism, environmental toxins, hypometabolism and dysfunctional weight set-point.

Leptin resistance is described as a condition in which overweight individuals are unable to respond to the hormone’s signals appropriately, leading to a starvation response in the body as well as hypothyroid symptoms at the cellular level where they are more difficult to detect.

Holtorf treats leptin resistance in patients with a class of medications that are typically reserved for controlling blood sugar levels in diabetics.

A suppressed or "wrecked" metabolism is another cause of obesity commonly cited by Holtorf.

Holtorf claims the metabolism, when subjected to repeated or overzealous dieting and exercise, will regulate itself by repressing thyroid hormone levels in the body, resulting in a hypothyroid state.